KATIA MORENO: Open Payments
NPI 1538621693 · MCALLEN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$750 in 39 payments from 13 companies in 2025. Trend: 2023 $709 · 2024 $473 · 2025 $750
Food & beverage: $750
| Company | Payments | Amount |
|---|---|---|
| Celgene Corporation | 11 | $155 |
| Novartis Pharmaceuticals Corporation | 5 | $98 |
| ABBVIE INC. | 3 | $74 |
| Genentech USA, Inc. | 3 | $71 |
| E.R. Squibb & Sons, L.L.C. | 3 | $64 |
| Gilead Sciences, Inc. | 3 | $61 |
| Astellas Pharma US Inc | 2 | $43 |
| Daiichi Sankyo Inc. | 2 | $40 |
| GlaxoSmithKline, LLC. | 2 | $37 |
| PUMA BIOTECHNOLOGY, INC. | 2 | $35 |
Products named: REBLOZYL, OPDUALAG, Trodelvy, VENCLEXTA, Fabhalta, Enhertu, Tecentriq, SCEMBLIX.
Industry payments across TX — which companies pay providers there.
